key: cord-0051619-m2355ho0
authors: Unni, Sruthi; Aouti, Snehal; Thiyagarajan, Saravanamuthu; Padmanabhan, Balasundaram
title: Identification of a repurposed drug as an inhibitor of Spike protein of human coronavirus SARS-CoV-2 by computational methods
date: 2020-10-16
journal: J Biosci
DOI: 10.1007/s12038-020-00102-w
sha: afcd6ca1e8c32a5b8912b3e3793e83359d45453f
doc_id: 51619
cord_uid: m2355ho0

Severe acute respiratory syndrome coronavirus (SARS-CoV-2) is an emerging new viral pathogen that causes severe respiratory disease. SARS-CoV-2 is responsible for the outbreak of COVID-19 pandemic worldwide. As there are no confirmed antiviral drugs or vaccines currently available for the treatment of COVID-19, discovering potent inhibitors or vaccines are urgently required for the benefit of humanity. The glycosylated Spike protein (S-protein) directly interacts with human angiotensin-converting enzyme 2 (ACE2) receptor through the receptor-binding domain (RBD) of S-protein. As the S-protein is exposed to the surface and is essential for entry into the host, the S-protein can be considered as a first-line therapeutic target for antiviral therapy and vaccine development. In silico screening, docking, and molecular dynamics simulation studies were performed to identify repurposing drugs using DrugBank and PubChem library against the RBD of S-protein. The study identified a laxative drug, Bisoxatin (DB09219), which is used for the treatment of constipation and preparation of the colon for surgical procedures. It binds nicely at the S-protein–ACE2 interface by making substantial π-π interactions with Tyr505 in the ‘Site 1’ hook region of RBD and hydrophilic interactions with Glu406, Ser494, and Thr500. Bisoxatin consistently binds to the protein throughout the 100 ns simulation. Taken together, we propose that the discovered molecule, Bisoxatin may be a promising repurposable drug molecule to develop new chemical libraries for inhibiting SARS-CoV-2 entry into the host.

Severe acute respiratory syndrome coronavirus (SARS-CoV) is a deadly pneumonia virus in humans (Drosten et al. 2003; Ksiazek et al. 2003) . The term ''coronavirus'' is named from the 'corona'-like or 'crown'-like morphology observed for these viruses in the electron-microscopy images (Gui et al. 2017) . SARS-CoV emerged in the Guangdong province of China in 2002 and spread to five continents through air travel routes, infecting about 8000 people and causing 774 deaths. Another deadly coronavirus, SARS-CoV-2 emerged in December 2019 in Wuhan, Hubei province of China is associated with an ongoing outbreak of atypical pneumonia pandemic, COVID-19. The World Health Organization (WHO) has declared that the SARS-CoV-2 epidemic is a public health emergency of international concern. There have been outbreaks worldwide after China including, Italy, Iran, France, Spain, Germany, the UK, the US, India, and so on. The WHO reported that as on 22 July 2020, there are about 14.7 million confirmed cases, including 612,000 deaths in more than 70 countries worldwide. In India, there are more than 1.2 million confirmed cases, including 29, 890 deaths. The current situation clearly evidenced that transmission of the disease is massive in a short period, with thousands of new patients diagnosed daily.

Common symptoms of the coronaviral infection include respiratory problems, fever, dry cough, shortness of breath, nasal congestion, sore throat, and diarrhea (Rothan and Byrareddy 2020) . In severe cases, the infection causes pneumonia, severe acute respiratory syndrome, kidney failure, and eventually to mortality. The cause of death is respiratory failure, shock, or multiple organ failure. There is no specific treatment for COVID-19 to date. Hence, discovering pharmaceutically active antivirals and/or vaccines specific to SARS-CoV-2 is imminent under the present worldwide crisis.

SARS-CoV-2 (COVID-19) is highly homologous to SARS-CoV. SARS-CoV-2 genome has ten open reading frames (ORFs) . Based on the sequence alignment of SARS-CoV-2 with SARS-CoV, the multiple functional proteins were speculated (Sardar et al. 2020; Wu et al. 2020) . ORF1ab encodes polyprotein 1ab. Two proteases, PL Pro and 3CL Pro , cleave the pp1ab protein at different sites to yield multiple proteins involved in the transcription and replication process of viral RNA. The proteolytic process of pp1ab gives 15 non-structured proteins. ORF2-10 encodes viral structural proteins, including S, M, N, and E proteins, and other auxiliary proteins. The S, M, and E proteins are responsible for the viral coating while the N-protein is essential for packing the RNA genome.

The transmembrane glycoprotein Spike (S-protein) is essential for the coronavirus entry into a host cell (Tortorici and Veesler 2019) . The S-protein forms a homotrimer that protrudes from the viral surface. The S-protein comprises two functional subunits (S1 and S2). The S1 domain directly interacts with the host cell receptor, while the S2 domain is responsible for the fusion of the viral and cellular membrane (Li et al. 2003 (Li et al. , 2005 Xiao et al. 2003) . The S1 domain possesses the receptor-binding domains (RBDs) and contributes to the stabilization of the prefusion state of the membrane-anchored S2 subunit, which involves fusion machinery (Gui et al. 2017; Walls et al. 2017) . The S1 domain directly interacts with angiotensin-converting enzyme 2 (ACE2) of the host to enter into the host cell (Song et al. 2018; Lan et al. 2020; Shang et al. 2020; Yan et al. 2020) . The S-protein of SARS-CoV is highly homologous to that of the recent pandemic SARS-CoV-2 . In March 2020, the structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein have been reported (Walls et al. 2020) . The structure of the full length of spike protein except the membrane-binding region was determined by cryo-EM. It was revealed that the Spike domain of the recent SARS-CoV-2 possesses a few additional features in comparison to the earlier SARS-CoV strain. The substitution of some residues on the RBD (receptor binding domain) from SARS-CoV to the recent SARS-CoV-2 (Arg426?Asn439, Tyr484?Gln498, Thr487?Asn501, Tyr442?Leu445, Leu443? Phe456, Phe460?Tyr473, Asn479?Gln493, and Val404?Lys417) was observed to increase the binding affinity of the spike RBD domain to the ACE2 receptor and provide a more compact conformation Yan et al. 2020) . The superposition of the ACE2 with the RBD domain of the full-length spike protein determined that the interaction with the openconformation of the latter was in higher compliance compared to its closed-conformation, which results in steric clashes between the two proteins.

Targeting the SARS-CoV-2 virus can be broadly divided based on the two stages: (1) the pre-fusion stage; and (2) the post-fusion stage. The pre-fusion stage targets the ACE2 receptor recognition of the RBD domain on the spike protein (S1 domain) and the consequential membrane fusion (S2 domain), leading to the development of prophylactic vaccines, antibodies and antiviral drug compounds (Xia et al. 2020a, b) . The post-fusion stages involve targeting the viral envelope shedding and replication after the viral entry within the host cells. Though the Indian origin of SARS-CoV-2 is highly homologs to SARS-CoV-2 of other countries (China, Italy, and the USA), few mutations were observed in ORF1ab, Nsp2, Nsp3, helicase, ORF8 protein and S-protein of Indian SARS-Co-V-2 (Sardar et al. 2020) . As the glycosylated S-protein is exposed to the surface and is essential for entry into the host, the S-protein can be considered as a first-line therapeutic target for antiviral therapy and vaccine development. While we were preparing the manuscript, a few works were reported in identifying small molecule inhibitors of S-protein by computational studies. For instance, chloroquine and its derivatives, including hydroxychloroquine were shown to bind the S-protein-ACE2 interface (Beura and Chetti 2020). Sandeep and McGregor (2020) also predicted that hydroxychloroquine and azithromycin bind to the S-protein to inhibit the ACE2 interaction. From a library comprising 9091 FDA approved drugs, the ivermectin drug was shown to bind to the S-protein interface (de Oliveira et al. 2020) .

To find the repurposable drug molecules to inhibit the Spike protein interaction with the host receptor, ACE2, we performed virtual screening for the receptorbinding domain (RBD) of S-protein against the Drug-Bank and PubChem libraries and subsequently carried out molecular dynamics simulation studies on selected compounds. Here, we discuss a discovered repurposable drug, Bisoxatin (DB09219), a laxative drug, which binds substantially at the S-protein -ACE2 interface, and it may be a robust repurposable drug to develop new chemical libraries for inhibiting SARS-CoV-2 entry into the host. . The structure was selected based on the structure quality and completeness of the RBD domain. In order to prepare the protein for docking, the ACE2 receptor was removed from the complex, and the S-protein was minimized and converted to pdbqt format using AutoDockTools.

2.1.3 Docking parameters: Molecular docking helps predict the predominant binding pose of a ligand with a protein and analyze the inhibitory interactions between them. Here, molecular docking studies were carried out using AutoDock Vina version 1.1.2 (Trott and Olson 2010) . Blind docking was carried out scanning the entire protein surface to get the ligands binding specifically to the ACE2 -S-protein interaction site. The docking parameters were kept to default. The docking grid size in X, Y, Z dimensions was set at size_x = 60.00 Å , size_y = 60.00 Å and size_z = 60.00 Å , respectively and centered at cen-ter_x = -32.22, center_y = 25.80 and cen-ter_z = 21.19. The exhaustiveness was kept at 9, with all other parameters kept default.

The docking results were processed using python script process_VinaResults.py available in MGL tools. The ligands were evaluated based on their binding free energy and the binding site. The ligands which bind at the S-protein-ACE2 interface only were selected for further evaluation. Interactions between the selected best hits and the macromolecule were analyzed using PyMol version 1.3 (Schrodinger 2017).

The docked pose of the selected ligands in complex with the RBD domain of the S-protein was prepared for further studies using atomistic molecular dynamic (MD) simulations (Bowers et al. 2006) . The Desmond module from the D.E. Shaw group was utilized for the MD setup (Bowers et al. 2006) . The ligand complexes were assigned and optimized with hydrogen atoms wherever required, checked for other atomic penalties, and minimized before the preparation of the solvation box. The RBD domain in complex with the respective ligands was solvated in a cubic box of water molecules at minimized volume. The solvated water box was generated and minimized using the steepest descent method until a gradient threshold of 1.0 kcal/mol/Å was reached with a minimum step size of 10. The Coulombic interactions were cut-off at 9.0 Å . The default force constant was applied, and no other restraints on the protein and solvent molecules were used during the minimization process. The production run consists of 8 stages, including the pre-relaxation of the protein-ligand complexes. The simulation run was performed at 300 K and 1.01325 bar pressure. The production run was carried out for a simulation time of 100ns. The trajectory frames were written into result files for every 50ps. The resultant 2000 frame trajectory was analyzed using both Desmond (Bowers et al. 2006) and Maestro (Release 2017) modules from the Schrödinger Suite. The PyMOL software (Schrödinger 2017) was also used for visual inspection of the cluster analysis results.

The simulated complexes were subjected to MM-GBSA (molecular mechanics combined with generalized Born and solvent-accessible surface area solvation) calculations to estimate the protein-ligand binding free energies Genheden and Ryde 2015) . The MM-GBSA scoring was performed using the Prime MM-GBSA script available in Prime module v5.6 of the Schrödinger Suite 2019-2 (Lyne et al. 2006; Du et al. 2011) . The 100ns MD trajectories were first stripped to remove the explicit solvent molecules. The trajectories were then split into total of 100 frame snapshots with 1000 ps step size. A continuum solvent model VSGB 2.1 (variable-dielectric generalized Born model) and OPLS3e force field were used for energy evaluations Roos et al. 2019) . To predict the induced fit effect of ligand, the binding site optimization comprising prime sidechain predictions and minimizations was also done. For each frame, the binding free energy of ligand and receptor is estimated using the following equation (1) :

where G complex , G protein , and G ligand are the prime energies of optimized complex, free receptor and free ligand. The separate free energy terms for complex, protein, and ligand are calculated for each snapshot using equation (2):

where DE MM corresponds to the average molecular mechanical energy and includes the electrostatic and van der Waals potentials in the molecular mechanical force field, given in equation (3), and DG solv is the solvation free energy obtained from summation of polar and non-polar contributions from equation (4). The polar solvation free energy is calculated using the generalized Born (GB) model, whereas the non-polar solvation free energy is obtained by solving a linear relation to solvent-accessible surface area. TDS is the absolute entropy solved using normal mode analysis of vibrational frequencies.

The final binding free energy reported is the average of the 100 snapshots. Additionally, to relate the stability of ligands at the binding site and its binding affinity, the MM-GBSA calculations were performed on representative frames from each cluster.

The receptor-binding domain (RBD domain) of the SARS-CoV-2 spike protein (S-protein) was selected as the drug target towards the screening of antiviral compounds against the 2019 pandemic SARS-CoV-2 (figure 1A). Superposition of the cryo-EM structure of Spike protein (open state) (PDB ID: 6VYB) with the crystal structure of the RBD domain in complex with ACE2 receptor (PDB ID: 6LZG) revealed a model impression of existent interaction between the two proteins (figure 1B, C). The DrugBank and PubChem databases were used for virtual screening studies (Bolton et al. 2008; Wishart et al. 2018 ). The compounds considered for the study from both the databases fulfilled the Rule of Five criteria (Lipinski 2004) . The selected compounds from the docking studies were visually inspected for the critical interactions that could disrupt the protein-protein interactions (PPI) between the S-protein of the SARS-CoV-2 virus and the human ACE2 receptor, thus potentially inhibiting the entry of the viral particle into the human; thereby, preventing the replication of the viral load. The intermolecular interface region for the docking studies was studied carefully. The blind docking studies were performed to eliminate any biased interactions that would be significantly weak in real-time binding studies. The binding site was divided into three regions based on the electrostatic surface region at the S-protein -ACE2 interface, namely, Site 1, Site 2, and Site 3 (figure 2A). The hydrophilic 'Site 1' region comprises of the residues Gly446, Tyr449, Gly496, Gln498, Thr500, and Asn501 on the S-protein and interacts with the residues Asp38, Tyr41, Gln42, Lys353 and Asp355 on the ACE2 receptor surface (figure 2B). The moderate hydrophilic 'Site 2' region comprises of the residues Lys417 and Gln493, which interact with the residues Asp30 and Glu35 of the ACE2 receptor ( figure 2C ).

The 'Site 3' region, which is also moderate hydrophilic, consists of the residues Ala475 and Asn487 on the S-protein and interact with the residues Ser19, Glu24, and Tyr83 of ACE2 (figure 2D). On further detailed analysis, the topology of the binding site indicated a substantial hydrophilic region on the head end of the 'Site 1' region. The 'Site 1' also houses a very prominent hydrophobic cleft produced by the residues Tyr495, Phe497, and Tyr505 (figure 2E) . This cleft does not indulge in interactions with the ACE2 receptor surface but seems to be an implementable strategy while designing drugs for the S-protein binding to inhibit the receptor interaction. The cleft is followed by the 'Site 2' residues, which provide a good hook position for the probable drug compounds. There are many hydrophilic non-interacting residues like Arg403, Glu406, and Tyr453 in the 'Site 2 region', which again provide a possible drug designing strategy to inhibit ACE2 (figure 2E).

For the DrugBank library, the docking studies revealed that the top-most binding compounds (seven ligands) possess docking scores ranging between -7.5 and -7.0 kcal/mol (table 1). The compounds which were showing site-specific interactions were visually inspected to determine their viability in hampering the ACE2 receptor interactions. Four compounds were further selected for MD simulation studies based on the interactions shown below. The top seven compounds, including the compounds selected for the MD study, are described below.

3.1.1 Mefloquine (DB00358): Mefloquine, an antimalarial drug, is very active against Plasmodium falciparum as well as against malarial parasites resistant to chloroquine and making it a highly efficient drug against malaria (Palmer et al. 1993; Nosten et al. 2000) . The compound shows good hydrophilic interaction with S-protein from a partial portion of Site 1 region extending to the 'Site 2' region (figure 3A). The two trifluromethyl moieties on the quinolinyl core significantly interact with the 'Site 1' residues (Gly496, Asn501, and Tyr505) and Site 2 residues (Tyr453 and Ser494). The piperidyl methanol moiety interacts with the residue Asn501. Additionally, the quinolinyl core and piperidyl ring stack on the residue Tyr505 in edge to face and face to face p-p interactions. The substantial loss of intermolecular interaction of Lys353 of ACE2 may occur when Mefloquine binds to S-protein at the predicted binding site. The residues in and around 'Site 1' and 'Site 2' form a good binding site for ligands interactions. The topology for the binding site can be divided as the hydrophobic cleft, 'hook 1', and 'hook 2' regions. The hydrophobic cleft is a hotspot for the binding of compounds with strong aromatic cores. The hook1 and hook2 regions, which comprise of hydrophilic interactions, provide good support to increase interactions.

Hetacillin is a b-lactam antibiotic that was used to treat bacterial infections (Hardcastle Jr et al. 1966; Smith and Hamilton-Miller 1970) . It was later withdrawn as it offered a lesser therapeutic value than the ampicillin derivatives. The compound is positioned in the hydrophobic cleft and the hook region of 'Site 2' (figure 3B). The imidazolidine moiety interacts with Tyr453, and the azabicyclo part of hetacillin interacts extensively with Glu406 of the 'Site 2' region. The phenyl moiety contributes to hydrophobic interaction with Tyr505. The intermolecular interaction of Lys353 of ACE2 may also be inhibited when Hetacillin binds to S-protein at the predicted binding site. and Tyr453 ( figure 3C ). The benzoyl and the hydrotropate moiety wraps the residue Tyr505 through p-p stacking interactions. The hydroxyl group from the benzoyl moiety interacts with the Gly496. Although the compound occupies the binding site, it does not disrupt any mandatory interactions between the spike-ACE2 interfaces, except the Lys353 interaction, which may disrupt by the compound.

3.1.4 Phenolphthalein (DB04824): Phenolphthalein is a laxative drug used for alimentary tract clearance before the surgical procedure (Gaginella et al. 1994) . Though it has been discontinued in Canada on the basis of being carcinogenic in nature, many countries still continue the usage of the drug (Coogan et al. 2000) .

The compound consists of twin hydroxylphenyl moieties, one of which, along with the benzofuranone portion, encloses the Tyr505 through p-p stacking interactions ( figure 3D ). The other hydroxylphenyl group substantially occupies the region where ACE2 interacts in the 'hook 1' region. The predicted docking pose of the compound wards off many important hydrophilic interactions that occur at the spike-ACE2 interface.

3.1.5 Bisoxatin (DB09219): Bisoxatin, also a laxative drug, has been used as a stimulant for intestinal peristalsis, thus treating constipation disorders and also for preparation of the colon for surgical procedures (Rider 1971) . The overlap of the drug positioning in the binding site of S-protein reveals a similar mode of binding, as found in the phenolphthalein binding ( figure 3D ). The benzoxazinone moiety of Bisoxatin and the benzofuranone portion of Phenolphthalein are overlapped each other in the binding site. A weak hydrogen bond is observed between the ligand and Thr500. Similar to Phenolphthalein, as described above, the hydroxylphenyl groups place itself to make p-p interactions with Tyr505 and to block the site where the interactions occurred by the ACE2 residues at the 'hook 1' region.

3.1.6 Riociguat (DB08931): Riociguat is used to treat pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension to improve exercise capacity and delay clinical worsening (Ghofrani et al. 2013a, b) . The pyrimidinyl and methyl carbamate group interacts with Tyr453, whereas the pyrazolopyridine and fluorobenzyl groups stack against Tyr505 through p-p interactions ( 

For the PubChem library, docking studies revealed the best hits with binding free energy ranging from -8.9 to -7.6 kcal/mol, which has been listed along with their functions in table 2. The interaction analysis of the top seven hits, which demonstrated site-specific binding, including the three compounds selected further for molecular dynamics study, is given below.

Talazoparib is an antineoplastic agent that selectively binds to poly (ADP-ribose) polymerase (PARP) enzymes and inhibits the PARP mediated DNA repair (Hoy 2018) . The flurobenzene rings wrap around Try505, forming p-p and p-p T-shaped aromatic interactions ( figure 4A ). The piperidine amine engages in hydrogen bonding with the 'Site 1' residues Gly496 and Asn501.

A diaminouracil derivative possesses potential anti-oxidative and anti-inflammatory activities (Goto et al. 2002) . The trimethylphenol moiety of the compound is involved in multiple interactions with the 'hook 1' residues, Asn501 and Gly496, and the residues from the hydrophobic cleft ( figure 4B ). The formation of p-p T-shaped interactions and hydrogen bonding with the carbonyl group of Tyr505 leads to its anchorage at the binding site. The amine groups show hydrogen bond interactions with Tyr453 in 'Site 2'. Though the compound contributes intermolecular interactions with the binding site residues, it does not hinder the ACE2 -S-protein interactions.

An inhibitor of lipoxygenase enzyme activity and prevents the oxidation of arachidonic acid to 5-hydroperoxyeicosatetraenoic acid by 5-lipoxygenase (Delorme et al. 1996) . It also reduces the leukotrienes B4 biosynthesis. The naphtonitrile and benzene moieties display p-p stacked and p-p T-shaped interactions with Tyr505. The dioxabicyclooctanol moiety interacts with Gly496 in 'Site 1' and the 'hook 2' residue, Arg403 (figure 4C). It also forms a hydrogen bond with Ser494. Moreover, the compound also interacts with Asn501 of 'Site 1' and completely occupies the position of Lys343 of ACE2. The docked pose of the ligand positioned at 'Site 1' suggests significant disruption may occur when S-protein interacts with ACE2.

Lensiprazine is an antipshycotic agent with the bifunctional activity of dopamine D2 receptor antagonism and serotonin reuptake inhibition (Smid et al. 2005) . The docked pose of the compound, which overlaps with the ACE2 interacting region, suggests that the compound may inhibit the ACE2 interaction with S-protein. The methylbenzoxazinone moiety interacts with the 'Site 1' residues Gly496, Asn501, and displays p-p T-shaped interactions with Tyr505 ( figure 4D ). The fluoroindole moiety displays significant interactions with the 'Site 2' residue Tyr453 and p-alkyl interactions with Lys417. The amine group of fluoroindole forms a hydrogen bond with Glu406.

3.2.5 CID2403: Bisindolylmaleimide VIII has lesser selectivity and potency towards protein kinase C as compared to CID2404 due to the presence of an amine side chain (Muid et al. 1991) . It is patented under Severe acute respiratory syndrome coronavirus as nucleic acids and proteins from SARS coronavirus (US2006257852) (Rino et al. 2004) . The propane amine group attached to the indole ring interacts with Tyr453 of 'Site 2' (figure 4E). The indole rings stack the Tyr505 by p-p interactions.

3.2.6 CID2404: Bisindolylmaleimide X is an inhibitor of protein kinase C with potential anti-inflammatory and anti-asthmatic activities (Muid et al. 1991) . The compound belongs to the class of organic compounds known as n-alkylindoles. The indole rings stack around Tyr505, forming edge to face and face to face strong aromatic interactions ( figure 4F ). It is also patented under US2006257852 (Rino et al. 2004 ). The indole ring and pyrroledione moiety contribute hydrogen bonds with Tyr505 and Gly496, respectively. The position of the compound and its interaction at 'Site 1' of S protein demonstrates significant disruption of the ACE2-spike protein interactions. Both CID2404 and CID2403 interrupt the ACE2 Lys343 interactions, and their binding pose indicates they might be able to break the 'Site 1' interactions with the ACE2 receptor.

3.2.7 CID7073228: Silymarin is a phytomedicine extracted from milk thistle seeds. Along with its hepatoprotective effects, it is also known for antioxidant, antiviral, anti-inflammatory, and anti-fibrotic activities (Soleimani et al. 2019; Xie et al. 2019) . It exhibits interactions with both 'Site 1' and 'Site 2' residues, thereby inhibiting His34 and Lys343 of ACE2 ( figure 4G ). The methoxyphenol moiety stacks with Tyr505 by an edge to face aromatic interaction and leads to many hydrogen bonding with the 'Site 1' residues (Gly496, Asn501, and Tyr505). The dihydrobenzodioxinylmethanol moiety forms interactions with Gly496, Ser495 in 'Site 1', and the 'Site 2' residues (Arg403 and Tyr453). Additionally, the resorcinol group engages in hydrophobic interactions with the aliphatic side chain of Lys417 in 'Site 2

3.3.1 DrugBank molecules: Further, MD studies were performed on the selected DrugBank molecules - A comprehensive analysis of the polar and non-polar interactions established by the molecule DB09219 was done throughout the simulation. The analysis revealed important electrostatic interaction around the 'Site 1' region. The majority of the interactions were formed by the residues Arg403, Ser494, Gly496, and Asn501 through direct and water-mediated hydrogen bond contacts (figure 7A, B) similar to the RBD-ACE2 contact (Malik et al. 2020) . The residues Tyr453, Gln494, Gly495, and Tyr505 contribute to the watermediated hydrogen bonding through most of the simulation. Based on the RMSD, cluster, contact and visual analysis, the simulation shows a slight change in the binding site around 75 ns, causing two different cluster conformations as well as differential contact analysis. We speculate that the flip over establishes new contacts with residues Gly446, Gly447, and Tyr449. Additionally, the hydrophobic contact pattern found with the residues Tyr449 and Tyr505 reveals stark complementarity leading to speculations that the ligand is under constant hydrophobic interactions (figure 7C). Taken together, the MD studies on these drug molecules substantiated that Bisoxatin might be a possible lead towards inhibition of Spike-ACE2 interactions.

The PubChem compounds though showed good binding energies, most of them tend to bind strongly in the hydrophobic cleft and not to interfere with the ACE2 -Spike protein interactions. Therefore, only two compounds (CID2404 and CID9890128) were selected for the simulation study.

The RMSD of the protein backbone and ligand atoms were calculated for RBD of SARS CoV2 Spike Protein in complex with PubChem compounds CID2404 and CID9890128 against their initial structures ( figure 8A ). Both the complexes showed no significant fluctuations over the 100ns simulation time and stabilized at * 2.5 Å . In order to check the stability of compounds at the binding site predicted by docking, the ligand RMSD with respect to protein was -20.15 calculated and analyzed. The CID9890128 complex showed very high fluctuation from 20 -55 ns, pointing to extreme changes in the ligand-binding ( figure 8B ). The CID2404 complex shows stable RMSD after 20ns of simulation (figure 8B). The higher RMSD values for both the compounds compared to the initial frame indicate a change in the initial binding position. The RMSF gives average residual mobility throughout simulation in a structure. RMSF of each complex was calculated and plotted against the residue number ( figure 8C ). Similar to the results of DrugBank compounds, the high fluctuation is observed in the loop region Gln474-Asn487. The validation of ligand positioning was done through trajectory cluster analysis ( figure 8D ). The number of clusters and cluster ratios for each of the ligand complex is given in table 4. The ligands CID2404 and CID9890128 exhibit poor cluster rations as they do not show binding to the target site and instead exhibit complete disruption of protein interactions as in the latter case.

To determine the interactions formed by the compounds with the residues at ACE2 -S protein binding site, hydrogen bond profiles were calculated between the compounds and the selected residues. Overall, CID2404 forms three hydrogen bonds, and CID9890128 forms two hydrogen bonds. The compound CID2404 interacts with the 'Site 1' residues Thr500, Gln498, and the 'Site 2' residue Ser494 during the simulation time (not shown). It was observed that the compound moves away from the initial binding site towards 'Site 3' (figure 8D). After 25 ns, it loses the initial interactions with Tyr505 and gets in close proximity of Leu452, Phe490, and Leu492, forming aromatic interactions. The compound CID9890128 shows interactions initially with Ser494 and Thr500. Its cluster analysis data shows that CID9890128 is moving away from the binding site (not shown). The initial interactions observed with Tyr505 were lost in the simulation course for both the compounds.

The MM-GBSA analysis was performed for the selected four ligands from the DrugBank database and the selected two ligands from the PubChem database. The trajectories of the selected protein-ligand complexes were sliced into periodical 100 snapshots, each of which was used for making Prime MM-GBSA calculations in the Schrodinger suite. The total binding energy trend of each complex at an interval of 1ns per snapshot is given in figure 9 . The running average values of different components of the calculated MM-GBSA binding free energies are shown in table 5. On analyzing the individual energy components, it is indicated that the van der Waals and electrostatic energies from the coulombic interactions form the major contribution to the binding free energy. The molecules, DB09219, and CID2404 showed the lowest binding free energy values with highly favorable van der Waals energies indicating the establishment of hydrophobic interactions with the surrounding residues. This high energy component validates the proximity of the ligand to the hydrophobic cleft, as discussed earlier. Additionally, the lipophilic energies indicate to be supporting the van der Waals interactions. These hydrophobic contacts play a crucial role in the stability of the ligands at the binding pocket. The electrostatic contribution to binding energy is comparable for all compounds except CID9890128 and DB00358 (table 5). The coulombic trend in the best-binding compound, DB09219, revealed the energy-dip post 70ns of trajectory, indicating the loss of electrostatic interactions. Interestingly, a comprehensive hydrogen bond analysis indicates that Gly496 and Asn501 show hydrogen bonds trend (figure 7A) that matches with the coulombic trend (figure 9A). The visual inspection revealed that the loss of this interaction is accompanied by a slight change in the binding site. Since the residues, Gly496 and Asn501, are some of the essential residues in the RBD-ACE2 interaction at the 'Site 1', we speculate that they might be critical residues for the competitive binding at the interface.

In addition, the binding energy analysis was performed for the clustered poses to differentiate the frames contributing and depleting the energy values. For the DrugBank compounds, DB00358 and DB04824, the total binding energy values indicate that higher cluster sizes contribute to the depletion of the overall average energy values (table 3) . For the compound, DB12301, Cluster #1, which possesses the largest cluster size, exhibits higher binding energy compared to the other clusters. However, the significant energy values of DB09219 are consistent in both the clusters as well as better compared to other ligands, suggesting that the DB09219 compound indeed binds substantially to the S-protein. For the PubChem compounds, CID2404 indicates consistent binding energy values between the two clusters but moderately lower than that for the compound, DB09219 (table 4) .

In conclusion, virtual screening, docking, molecular dynamics simulation and MM-GBSA studies of the DrugBank and PubChem libraries against the receptorbinding domain (RBD) of S-protein yielded a robust repurposable drug molecule, Bisoxatin which significantly binds to the RBD domain at the RBD -ACE2 interface and thereby Bisoxatin may inhibit the binding of ACE2 to the Spike protein. Thus, we propose that the hit molecule, Bisoxatin, can be used as a lead molecule to develop new chemical libraries as inhibitors of the SARS-CoV-2 Spike protein to prevent the host cell interaction.

In-silico strategies for probing chloroquine based inhibitors against SARS-CoV-2

PubChem: integrated platform of small molecules and biological activities

Scalable algorithms for molecular dynamics simulations on commodity clusters

Doravirine: a review

Phenolphthalein laxatives and risk of cancer

Dioxabicyclooctanyl naphthalenenitriles as nonredox 5-lipoxygenase inhibitors: structure-activity relationship study directed toward the improvement of metabolic stability

Identification of a novel coronavirus in patients with severe acute respiratory syndrome

Molecular modeling study of checkpoint kinase 1 inhibitors by multiple docking strategies and prime/ MM-GBSA calculation

Nitric oxide as a mediator of bisacodyl and phenolphthalein laxative action: induction of nitric oxide synthase

The MM/PBSA and MM/ GBSA methods to estimate ligand-binding affinities

Riociguat for the treatment of chronic thromboembolic pulmonary hypertension

Riociguat for the treatment of pulmonary arterial hypertension

CX-659S: a novel diaminouracil derivative that has antioxidative and acute anti-inflammatory activities

Cryo-electron microscopy structures of the SARS-CoV spike glycoprotein reveal a prerequisite conformational state for receptor binding

The preparation and structure of hetacillin

Talazoparib: first global approval

update: improved access to chemical data

Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models

A novel coronavirus associated with severe acute respiratory syndrome

Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor

Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus

The VSGB 2.0 model: a next generation energy model for high resolution protein structure modeling

Structure of SARS coronavirus spike receptor-binding domain complexed with receptor

Lead-and drug-like compounds: the ruleof-five revolution

Accurate prediction of the relative potencies of members of a series of kinase inhibitors using molecular docking and MM-GBSA scoring

Interfacial Water Molecules Make RBD of SPIKE Protein and Human ACE2 to Stick Together

Combined molecular mechanical and continuum solvent approach (MM-PBSA/ GBSA) to predict ligand binding

AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility

A novel conformationally restricted protein kinase C inhibitor, Ro 31-8425, inhibits human neutrophil superoxide generation by soluble, particulate and postreceptor stimuli

Effects of artesunate-mefloquine combination on incidence of Plasmodium falciparum malaria and mefloquine resistance in western Thailand: a prospective study

Open Babel: An open chemical toolbox

Repurposing approved drugs as inhibitors of SARS-CoV

S-protein from molecular modeling and virtual screening

Treatment of acute and chronic constipation with bisoxatin acetate and bisacodyl. Double-blind crossover study

Severe acute respiratory syndrome coronavirus

OPLS3e: Extending Force Field Coverage for Drug-Like Small Molecules

The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak

Energetics Based Modeling of Hydroxychloroquine and Azithromycin Binding to the SARS-CoV-2 Spike (S)Protein -ACE2 Complex

Safety and efficacy of topical ketoprofen in transfersome gel in knee osteoarthritis: a systematic review

Comparative analyses of SAR-CoV2 genomes from different geographical locations and other coronavirus family genomes reveals unique features potentially consequential to hostvirus interaction and pathogenesis

The PyMol molecular graphics system, version 2.0. Schrödinger, LLC

Structural basis of receptor recognition by SARS-CoV-2

Synthesis, structure-activity relationships, and biological properties of 1-heteroaryl-4-[x-(1 H-indol-3-yl) alkyl] piperazines, novel potential antipsychotics combining potent dopamine d2 receptor antagonism with potent serotonin reuptake inhibition

Hetacillin: a chemical and biological comparison with ampicillin

Safety and toxicity of silymarin, the major constituent of milk thistle extract: An updated review

Cryo-EM structure of the SARS coronavirus spike glycoprotein in complex with its host cell receptor ACE2

Structural insights into coronavirus entry

AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading

Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein

Tectonic conformational changes of a coronavirus spike glycoprotein promote membrane fusion

Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus

Structural and functional basis of SARS-CoV-2 entry by using human ACE2

DrugBank 5.0: a major update to the DrugBank database

Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods

Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion

Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein

The SARS-CoV S glycoprotein: expression and functional characterization

Metabolism, transport and drug-drug interactions of silymarin

Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2